Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Moisés Lafuente (Barcelona, Spain), A. Navarro (Barcelona, Spain), S. Santasusagna (Barcelona, Spain), N. ViñOlas (Barcelona, Spain), J. Ramirez (Barcelona, Spain), G. Frigola (Barcelona, Spain), L. Molins (Barcelona, Spain), J. Castellano (Barcelona, Spain), S. Morales (Barcelona, Spain), C. MuñOz (Barcelona, Spain), M. Monzó (Barcelona, Spain), R. Marrades (Barcelona, Spain). The NANCI lncRNA-NKX2-1 gene duplex impacts prognosis in stage I NSCLC.. 2793

Member's Comments

No comment yet.

Related content which might interest you: NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Gender differences in the expression of double strand break genes in early non-small lung cancer (NSCLC) patients Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 The risk of distant metastases and prognosis prediction in early stage squamous cell lung cancer (SqCLC) by means of 3 microRNAs expression assessment Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011 Independent validation of prognostic value of 22 microRNAs (miRs) in stage I-II lung adenocarcinoma (AC) Source: Annual Congress 2012 - New mechanisms in non-neoplastic and neoplastic lung diseases Year: 2012 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 The long non-coding MALAT-1 RNA indicates a poor prognosis in NSCLC and induces migration and tumor growth Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Quantitative RT-PCR 3-gene expression signature predicts survival in early-stage non-small cell lung cancer (NSCLC) patients (pts) Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Independent prognostic und predictive value of blood vessel invasion (BVI) in curatively (R0) resected stage II and IIIA non-small cell lung (NSCLC) cancer patients Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 Prediction of long-term effect of anti-angiogenic therapy in lung cancer patients by monitoring early changes in circulating-tumor DNA (ctDNA). Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020